

World Journal of *Medical Genetics*

World J Med Genet 2013 February 27; 3(1): 1-4



Editorial Board

2011-2015

The *World Journal of Medical Genetics* Editorial Board consists of 345 members, representing a team of worldwide experts in medical genetics. They are from 51 countries, including Argentina (1), Armenia (1), Australia (5), Austria (2), Belgium (2), Brazil (5), Bulgaria (2), Canada (6), Chile (1), China (41), Croatia (1), Czech Republic (1), Denmark (3), Ecuador (1), Egypt (2), France (10), Germany (4), Greece (2), Hungary (1), India (12), Iran (7), Ireland (1), Israel (2), Italy (22), Japan (24), Latvia (1), Malaysia (2), Mexico (2), Netherlands (6), New Zealand (2), Norway (2), Pakistan (1), Peru (1), Poland (1), Portugal (1), Russia (2), Saudi Arabia (3), Serbia (1), Singapore (3), Slovenia (2), South Korea (7), Spain (17), Sweden (2), Switzerland (2), Thailand (3), Turkey (8), Ukraine (1), United Arab Emirates (1), United Kingdom (11), United States (103), and Uruguay (1).

EDITOR-IN-CHIEF

Hans van Bokhoven, *Nijmegen*

GUEST EDITORIAL BOARD MEMBERS

Chia-Hsiang Chen, *Zhunan*
 Ji-Yih Chen, *Taoyuan*
 Bor-Luen Chiang, *Taipei*
 Yu-Chen Hu, *Hsinchu*
 Hai-Gwo Hwu, *Taipei*
 Suh-Hang H Juo, *Kaohsiung*
 Hsien-Hsiung Lee, *Taichung*
 Yueh-Lun Lee, *Taipei*
 Chin-San Liu, *Changhua*
 Pei-Jung Lu, *Tainan*
 Chien-Kuo Tai, *Chiayi*
 Po-Nien Tsao, *Taipei*
 Wendy W H Weng, *Taipei*
 Jeng-Hsien Yen, *Kaohsiung*

MEMBERS OF THE EDITORIAL BOARD



Argentina

Jose Carlos Pirola, *Buenos Aires*



Armenia

Hasmik Mkrtchyan, *Yerevan*



Australia

Simon Easteal, *Canberra*
 Manuel B Graeber, *Camperdown*

Jeremy Jowett, *Melbourne*
 Karen Mather, *Randwick*
 Grant Morahan, *Perth*



Austria

Harald Aschauer, *Vienna*
 Anton Wutz, *Vienna*



Belgium

Teresinha Leal, *Brussels*
 Dirk van West, *Antwerp*



Brazil

Jeane E Lvisentainer, *São Paulo*
 Sharbel Weidner Maluf, *Porto Alegre*
 Milton O Moraes, *Rio de Janeiro*
 Fernando R Vargas, *Rio de Janeiro*
 Isabela Jube Wastowski, *Goiás*



Bulgaria

Spaska Stanilova, *Stara Zagora*
 Albena Todorova, *Sofia*



Canada

Regen Drouin, *Sherbrooke*
 Gonzalo Hortelano, *Ontario*
 William Jia, *Vancouver*

Sean Li, *Ottawa*
 Shiva M Singh, *Ontario*
 Li-Ting Song, *Toronto*



Chile

Jara S Lilian, *Santiago*



China

George G Chen, *Hong Kong*
 Volodymyr Dvornyk, *Hong Kong*
 Ning-Han Feng, *Nanjing*
 Shi-Ang Huang, *Wuhan*
 Wei Huang, *Shanghai*
 Chun-Yan Ji, *Jinan*
 Hong-Chuan Jin, *Hangzhou*
 Ke-Shen Li, *Zhanjiang*
 Zhuo-Zhuang Lu, *Beijing*
 Xiao-Ping Luo, *Wuhan*
 Wen-Bin Qian, *Hangzhou*
 Rong Rui, *Nanjing*
 Lun-Quan Sun, *Changsha*
 Qian Tao, *Hong Kong*
 George Sai-Wah Tsao, *Hong Kong*
 Ming-Rong Wang, *Beijing*
 Shi-Jie Wang, *Shijiazhuang*
 Wei Wang, *Beijing*
 Ji Wu, *Shanghai*
 Hua-Xi Xu, *Zhenjiang*
 Rui-An Xu, *Xiamen*
 Wei-Hua Yan, *Linhai*
 Rong-Cun Yang, *Tianjin*
 Bang-Ce Ye, *Shanghai*
 Rui-Xing Yin, *Nanning*
 Yi Zeng, *Beijing*

Xiao-Feng Zhu, *Guangzhou*



Croatia

Gordan Lauc, *Zagreb*



Czech Republic

Marie Lipoldova, *Prague*



Denmark

Vibeke Andersen, *Aabenraa*
Thomas V O Hansen, *Copenhagen*
Goutam Sahana, *Tjele*



Ecuador

Cesar Paz-Y-Miño, *Quito*



Egypt

Menha M A Swellam, *Giza*
Samia A Tentamy, *Cairo*



France

Christophe Chevillard, *Marseille*
Johanna Chluba, *Dijon*
Zdenko Herceg, *Lyon*
Enzo Lalli, *Valbonne*
James Lespinasse, *Chambéry*
Bernard S Lopez, *Fontenay aux Roses*
Eric Pasmant, *Clichy*
Kay-D Wagner, *Nice*
Qing Wang, *Lyon*
Georges Vassaux, *Nice Cedex*



Germany

Stefan Böhringer, *Essen*
Anibh Martin Das, *Hannover*
Gudrun A Rappold, *Heidelberg*
Hermona Soreq, *Jerusalem*



Greece

Roxani Angelopoulou, *Athens*
Voula Velissariou, *Athens*



Hungary

Bela Meleg, *Pecs*



India

Arvind Kumar Arya, *Meerut*
Prakash Sadashiv Gambhir, *Pune*
Katta MK Girisha, *Manipal*

Narendra Joshi, *Navi Mumbai*
Chinmay KumarPanda, *Kolkata*
Rajni Rani, *New Delhi*
Susanta Roychoudhury, *Kolkata*
Sudeep R Shah, *Mumbai*
Ranbir Chander Sobti, *Chandigarh*
Mandava Swarna, *Mumbai*
Meera Vaswani, *New Delhi*
Suresh P Vyas, *Sagar*



Iran

Yahya Daneshbod, *Shiraz*
Fariborz Ghaffarpasand, *Shiraz*
Mohammad H Modarressi, *Tehran*
Shirin Hasani Ranjbar, *Tehran*
Nader Tajik, *Tehran*
DM Kordi Tamandani, *Zahedan*
Alireza Zomorodipour, *Tehra*



Ireland

Ross McManus, *Dublin*



Israel

Aliza Shlomit Amiel, *Kfar-Saba*
Rachel Ben-Shlomo, *Tivon*



Italy

Francesco Acquati, *Varese*
Nenad Bukvic, *Foggia*
Gabriele Candiani, *Milan*
Antonio Cao, *Cagliari*
Marco Castori, *Rome*
Massimo Collino, *Torino*
Teresa Esposito, *Naples*
Antonia Follenzi, *Novara*
Tommasina Guglielmelli, *Turin*
Lidia Larizza, *Milan*
Fortunato Lonardo, *Benevento*
Marco Lucarelli, *Rome*
Laura Mandelli, *Bologna*
Antonio Musio, *Pisa*
Pier Giuseppe Pelicci, *Milan*
Daniela Perotti, *Milano*
Antonio M Persico, *Rome*
Enrico Pola, *Rome*
Giovanni Romeo, *Bologna*
Emanuela Signori, *Rome*
Alessio Squassina, *Cagliari*
Anna Stornaiuolo, *Milano*



Japan

Yutaka Hata, *Tokyo*
Mizukami Hiroaki, *Shimotsuke*
Johji Inazawa, *Tokyo*
Yasutomi Kamei, *Tokyo*
Tetsufumi Kanazawa, *Osaka*
Hiroyuki Kanzaki, *Miyagi*
Koichi Kawakami, *Shizuoka*
Akinori Kimura, *Tokyo*

Hiroshi Kunugi, *Tokyo*
Alexander Lezhava, *Yokohama*
Hisao Masai, *Tokyo*
Ryuichi Morishita, *Osaka*
Hitoshi Osaka, *Yokohama*
Masa-Aki Shibata, *Osaka*
Kazumi Suzukawa, *Tsukuba*
Masatoshi Tagawa, *Chiba*
Shin'ichi Takeda, *Tokyo*
Keizo Takenaga, *Shimane*
Hiroshi Tanooka, *Tokyo*
Takafumi Uchida, *Sendai*
Sho-ichi Yamagishi, *Kurume*
Toshiyuki Yamamoto, *Tokyo*
Norio Yasui-Furukori, *Hirosaki*
Kiyotsugu Yoshida, *Tokyo*



Latvia

Laima Tihomirova, *Riga*



Malaysia

Ravindran Ankathil, *Kelantan*
Hua Siew Gan, *Kelantan*



Mexico

Jose FMunoz-Valle, *Zapopan*
Gilberto Vargas-Alarcon, *Tlalpan*



Netherlands

Annemieke Aartsma-Rus, *Leiden*
Raoul CM Hennekam, *Amsterdam*
Anke H Maitland-van der Zee, *Utrecht*
Paul J Van Diest, *Utrecht*
Mannis van Oven, *Leiden*



New Zealand

Ryuji Fukuzawa, *Dunedin*
Christine M Morris, *Christchurch*



Norway

Kristian Tambs, *Oslo*
Martin Tesli, *Oslo*



Pakistan

Muhammad Naem, *Islamabad*



Peru

Gustavo F Gonzales, *Lima*



Poland

Piotr J Wysocki, *Poznan*

**Portugal**

Manuel R Teixeira, *Porto*

**Russia**

Anton V Kiselev, *Saint-Petersburg*
Yurov Yuri B, *Moscow*

**Saudi Arabia**

Khaled K Abu-Amro, *Riyadh*
Khawla S Al-Kuraya, *Riyadh*
Wael Mohamed Swelam, *Medina*

**Serbia**

Lidija Radenovic, *Belgrade*

**Singapore**

N Gopalakrishna Iyer, *Singapore*
Peter E Lobie, *Singapore*
Eng-King Tan, *Singapore*

**Slovenia**

Borut Peterlin, *Ljubljana*
Uros Potocnik, *Maribor*

**South Korea**

Byung-Hoon Jeong, *Anyang*
Jung Jin Kim, *Seoul*
Yonggoo Kim, *Seoul*
Taeg Kyu Kwon, *Taegu*
Seong-Wook Lee, *Yongin*
Taesung Park, *Seoul*
Han-Wook Yoo, *Seoul*

**Spain**

Salvador F Aliño, *Valencia*
David Araújo-Vilar, *Santiago De Compostela*
Victor Asensi, *Oviedo*
Ignacio Blanco-Guillermo, *Barcelona*
Judith Sanz i Buxo, *Catalonia*
Juan I Perez Calvo, *Zaragoza*
Javier S Castresana, *Pamplona*
Cristina Fillat, *Barcelona*
Karen Heath, *Madrid*
Adrián Llerena, *Badajoz*
Jose F Marti Masso, *San Sebastian*
Jose M Millan, *Valencia*
Juan Pie, *Zaragoza*
Jesus Prieto, *Pamplona*
Juan A Rey, *Madrid*
Miguel Chillon Rodriguez, *Bellaterra*
Maria E Saez, *Seville*

**Sweden**

Karin Klinga-Levan, *Skovde*
Mef Christina Nilbert, *Lund*

**Switzerland**

Angela Ciuffi, *Lausanne*
Daniel Schorderet, *Lausanne*

**Thailand**

Vorasuk Shotelersuk, *Bangkok*
Tewin Tencommao, *Bangkok*
Viroj Wiwanitkit, *Bangkok*

**Turkey**

Mehmet Necdet Akkus, *Mersin*
Julide Altinisik, *Balikesir*
Emrah Caylak, *Cankiri*
Merih Cetinkaya, *Bursa*
Ali Karaman, *Erzurum*
Mustafa Sahin, *Ankara*
Ahter Dilsad Sanlioglu, *Antalya*
Salih Sanlioglu, *Antalya*

**Ukraine**

Ludmila Livshits, *Kyiv*

**United Arab Emirates**

Bassam R Ali, *Al-Ain*

**United Kingdom**

Kristin Becker, *Cardiff*
Constantinos Demonacos, *Manchester*
David Jeremy Galton, *London*
Elaine Green, *Cardiff*
Wen G Jiang, *Cardiff*
Patrick J Morrison, *Belfast*
Elisabeth Nacheva, *London*
Mary Callaghan Nicol, *Cardiff*
James S Owen, *London*
David J Timson, *Belfast*
Eugene M Tulchinsky, *Leicester*

**United States**

Praveen R Arany, *Cambridge*
Nedal Arar, *San Antonio*
Richard G Boles, *Los Angeles*
Merlin G Butler, *Kansas*
Hai-Feng Chen, *Hayward*
J Don Chen, *Piscataway*
James Chen, *Jefferson*
Xiang-Ning Chen, *Richmond*
Paola Costa-Mallen, *Kenmore*
Qi Dai, *Nashville*

Shuo Dong, *Houston*
Yao-Shan Fan, *Miami*
Bing-Liang Fang, *Houston*
Peter J Francis, *Portland*
Xiao-Yi Gao, *Los Angeles*
Yu-Bin Ge, *Detroit*
Antonio Giordano, *Philadelphia*
Thomas J Giordano, *Ann Arbor*
Stephen J Glatt, *Syracuse*
WT Godbey, *New Orleans*
Dennis R Grayson, *Chicago*
Dong-Sheng Gu, *Indianapolis*
Zong-Sheng Guo, *Pittsburgh*
Hakon Hakonarson, *Philadelphia*
Wayne W Hancock, *Philadelphia*
David W Hein, *Louisville*
Hui-Xiao Hong, *Jefferson*
Ji-Fan Hu, *Palo Alto*
Shi-Le Huang, *Shreveport*
Ying Huang, *Syracuse*
Johnny Huard, *Pittsburgh*
Barbara H Iglewski, *Rochester*
Yurij Ionov, *Buffalo*
Jing-Fang Ju, *Stony Brook*
Berit Kerner, *Los Angeles*
Alisa E Koch, *Ann Arbor*
Paul C Kuo, *Maywood*
Robert R Langley, *Houston*
Eduardo C Lau, *Milwaukee*
K-H William Lau, *Loma Linda*
Mong-Hong Lee, *Houston*
Dawei Li, *New Haven*
Feng-Zhi Li, *Buffalo*
Shi-Bo Li, *Oklahoma*
Ming-Fong Lin, *Omaha*
Steven R Lindheim, *Cincinnati*
Feng Liu, *Chapel Hill*
Xiao-Qi Liu, *West Lafayette*
Yao-Zhong Liu, *New Orleans*
Yong-Jun Liu, *New Orleans*
Bo Lu, *Nashville*
Qun Lu, *Greenville*
Xing-Guang Luo, *West Haven*
James L Manley, *New York*
Viraj Master, *Atlanta*
Richard C McEachin, *Ann Arbor*
Jian-Feng Meng, *Kansas*
Duane A Mitchell, *Durham*
Yin-Yuan Mo, *Springfield*
Viktor Morozov, *Bethesda*
Srinivas Mummidi, *San Antonio*
Mayumi Naramura, *Omaha*
Swapan K Nath, *Oklahoma*
Muthu Periasamy, *Columbus*
Gwendolyn P Quinn, *Tampa*
Rajalingam Raja, *Los Angeles*
Rajagopal Ramesh, *Houston*
Jasti S Rao, *Peoria*
Charles J Rosser, *Orlando*
Mark A Rothstein, *Louisville*
Ananda L Roy, *Boston*
Dharambir K Sanghera, *Oklahoma*
Thomas Scholl, *Westborough*
Rong Shao, *Springfield*
Yuenian Eric Shi, *Roslyn Heights*
Shree Ram Singh, *Frederick*
Si-Hong Song, *Seminole*
Constantine A Stratakis, *Bethesda*
Manjunath N Swamy, *El Paso*
Ming Tan, *Mobile*
Bakhos A Tannous, *Charlestown*

Flora Tassone, *Sacramento*
Mustafa Tekin, *Miami*
Brad Therrell, *Austin*
Barry Trink, *Baltimore*
Tibor Valyi-Nagy, *Chicago*
Andre van Wijnen, *Worcester*
Chia-Yeng Wang, *Chicago*
Jean Yin Jen Wang, *La Jolla*
Pin Wang, *Los Angeles*

Li Wei, *Cleveland*
Qing-Yi Wei, *Houston*
Qi-Ze Wei, *Manhattan*
David A Weinstein, *Gainesville*
Mary Wilson, *Iowa*
Xiaoling Xuei, *Indianapolis*
Edward Kuo-Liang Yang, *Chandler*
Guang Yang, *Augusta*
Zeng-Quan Yang, *Detroit*

Lin Yao, *Augusta*
Si-Ming Zhang, *Albuquerque*
Xiaoliu Shaun Zhang, *Houston*
Tong Zhu, *Durham*



Uruguay

Jose Luis Badano, *Montevideo*



BRIEF ARTICLE

- 1 Malignant pheochromocytoma in neurofibromatosis; mutation screening of RET proto-oncogene, *VHL* and *SDH* gene
Hasani-Ranjbar S, Amoli MM, Noorani M, Ghadami M

APPENDIX I-V Instructions to authors

ABOUT COVER Editorial Board Member of *World Journal of Medical Genetics*, Gwendolyn P Quinn, PhD, Associate Professor, Moffitt Cancer Center-USF, College of Medicine, 12902 Magnolia Dr Mrc Cancont, Tampa, FL 33612, United States

AIM AND SCOPE *World Journal of Medical Genetics (World J Med Genet, WJMG, online ISSN 2220-3184, DOI: 10.5496)* is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJMG covers topics concerning genes and the pathology of human disease, molecular analysis of simple and complex genetic traits, cancer genetics, epigenetics, gene therapy, developmental genetics, regulation of gene expression, strategies and technologies for extracting function from genomic data, pharmacological genomics, genome evolution. The current columns of *WJMG* include editorial, frontier, diagnostic advances, therapeutics advances, field of vision, mini-reviews, review, topic highlight, medical ethics, original articles, case report, clinical case conference (Clinicopathological conference), and autobiography.

We encourage authors to submit their manuscripts to *WJMG*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

INDEXING/ABSTRACTING *World Journal of Medical Genetics* is now indexed in Digital Object Identifier.

FLYLEAF I-IV Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xin-Xin Che*
Responsible Electronic Editor: *Xiao-Mei Zheng*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Huan-Huan Zhai*

NAME OF JOURNAL
World Journal of Medical Genetics

ISSN
 ISSN 2220-3184 (online)

LAUNCH DATE
 December 27, 2011

FREQUENCY
 Quarterly

EDITOR-IN-CHIEF
Hans van Bokhoven, Professor, PhD, Department of Human Genetics and Cognitive Neurosciences, Radboud university Nijmegen Medical centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands

EDITORIAL OFFICE
 Jin-Lei Wang, Director
 Xiu-Xia Song, Vice Director

World Journal of Medical Genetics
 Room 903, Building D, Ocean International Center,
 No. 62 Dongsihuan Zhonglu, Chaoyang District,
 Beijing 100025, China
 Telephone: +86-10-85381891
 Fax: +86-10-85381893
 E-mail: wjmg@wjgnet.com
<http://www.wjgnet.com>

PUBLISHER
 Baishideng Publishing Group Co., Limited
 Flat C, 23/F, Lucky Plaza,
 315-321 Lockhart Road, Wan Chai,
 Hong Kong, China
 Fax: +852-6555-7188
 Telephone: +852-3177-9906
 E-mail: bpgoffice@wjgnet.com
<http://www.wjgnet.com>

PUBLICATION DATE
 February 27, 2013

COPYRIGHT

© 2013 Baishideng. Articles published by this Open Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

INSTRUCTIONS TO AUTHORS

Full instructions are available online at http://www.wjgnet.com/2220-3184/g_info_20100722180909.htm

ONLINE SUBMISSION

<http://www.wjgnet.com/esps/>

Malignant pheochromocytoma in neurofibromatosis; mutation screening of RET proto-oncogene, *VHL* and *SDH* gene

Shirin Hasani-Ranjbar, Mahsa M Amoli, Maasumeh Noorani, Mohsen Ghadami

Shirin Hasani-Ranjbar, Obesity and Eating Habits Research Center, Endocrinology and Metabolism Cellular and Molecular Sciences Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran 14114, Iran

Mahsa M Amoli, Maasumeh Noorani, Mohsen Ghadami, Endocrinology and Metabolism Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran 14114, Iran

Author contributions: Hasani-Ranjbar S performed clinical and biochemical tests and followed up the patient, writing and editing the final article; Noorani M prepared the first draft of the paper and helped in writing the manuscript; Amoli MM performed genetic evaluation for von Hippel-Lindau and succinate dehydrogenase complex subunits; Ghadami M performed genetic tests for RET proto-oncogene and helped in writing the manuscript.

Correspondence to: Shirin Hasani-Ranjbar, Endocrinologist, Obesity and Eating Habits Research Center, Endocrinology and Metabolism Cellular and Molecular Sciences Institute, Shariati Hospital, Tehran University of Medical Sciences, North Kargar Ave., Tehran 14114, Iran. sh_hasani@sina.tums.ac.ir

Telephone: +9821-8-8220037 Fax: +9821-8-8220052

Received: January 29, 2013 Revised: February 11, 2013

Accepted: February 20, 2013

Published online: February 27, 2013

Abstract

AIM: To investigate pathogenic mutations related to malignant pheochromocytoma in neurofibromatosis (NF).

METHODS: We present a patient with NF and metastatic pheochromocytoma in whom genetic screening for presence of pathogenic mutations in RET proto-oncogene, von Hippel-Lindau (*VHL*) and succinate dehydrogenase complex subunits B (*SDHB*) genes were investigated. RET proto-oncogene mutation screening for exons 10, 11, 13, 14, 15, 16 were examined by polymerase chain reaction (PCR) and direct DNA sequencing in patient. Mutation screening for exons 1, 2, 3 of *VHL* gene was carried out. Both forward and reverse strands

were subjected to direct sequencing after PCR amplification. The entire coding sequence of *SDHB* gene was screened for the presence of pathogenic mutations by PCR-sequencing.

RESULTS: A 45-year-old man presented with abdominal pain and hypertension over the previous year. The patient was a known case of neurofibromatosis type 1 (NF1) who presented at the age of 15 years with hyperpigmented and hypopigmented lesions. After complete evaluation for hypertension, biochemical tests and imagings indicated a malignant pheochromocytoma of 120 mm × 70 mm in size. The patient underwent left adrenalectomy, nephrectomy and splenectomy. After surgery the symptoms improved and blood pressure was controlled. After 5 years he was admitted again for evaluation of hypertensive crisis. Biochemical tests were again consistent with pheochromocytoma and disease relapse. Imaging studies and liver biopsy confirmed metastatic pheochromocytoma to the liver and para-aortic area. 131 Iodine-metaiodobenzylguanidine therapy was carried out. Genetic screening of *VHL* (exons 1, 2, 3), RET proto-oncogene (exons 10, 11, 13, 14, 15, 16) and *SDH* complex subunits revealed no pathogenic mutation.

CONCLUSION: We conclude that mutations in the *NF1* gene are responsible for the patient's clinical findings. However, would be helpful to further examine somatic mutations for a more precise study of genotype-phenotype correlation.

© 2013 Baishideng. All rights reserved.

Key words: Neurofibromatosis; Familial pheochromocytoma; Malignant pheochromocytoma; Metastatic pheochromocytoma; RET proto-oncogene; von Hippel-Lindau; Succinate dehydrogenase complex subunits

Core tip: Malignant pheochromocytoma associated with neurofibromatosis (NF) is very rare. We screened for all

possible mutations related to pheochromocytoma in a patient with NF and malignant pheochromocytoma but found no mutations. This negative result shows that the *NF1* gene is responsible for this rare presentation.

Hasani-Ranjbar S, Amoli MM, Noorani M, Ghadami M. Malignant pheochromocytoma in neurofibromatosis; mutation screening of RET proto-oncogene, *VHL* and *SDH* gene. *World J Med Genet* 2013; 3(1): 1-4 Available from: URL: <http://www.wjgnet.com/2220-3184/full/v3/i1/1.htm> DOI: <http://dx.doi.org/10.5496/wjmg.v3.i1.1>

INTRODUCTION

Pheochromocytomas and paragangliomas (PGLs) are catecholamine-secreting tumors, which arise from chromaffin cells of the adrenal medulla and extra-adrenal sites^[1]. Most pheochromocytomas are sporadic tumors. However some patients suffer from the disease as part of a familial disorder (15%-30%). There are several familial disorders associated with pheochromocytoma including von Hippel-Lindau (*VHL*) syndrome, multiple endocrine neoplasia type 2 (*MEN2*), neurofibromatosis type 1 (*NF1*), succinate dehydrogenase (*SDH*) complex subunit mutation-related tumors and occasionally *MEN1* syndrome. The approximate frequency of pheochromocytoma in these disorders is 50% in *MEN2*, 10%-20% in *VHL* syndrome, and 0.1%-5.7% with *NF1*^[2-5].

Malignant forms of catecholamine-secreting tumors are rare. The malignancy rate is variable from 2.4% to 26%. There are no histological proofs of malignancy for such tumors to date and the only accepted criterion is the presence of metastasis. The distant metastases are usually of hematologic origin, mostly involving bone, liver and lung^[2,3]. The prevalence of metastasis is up to 36%-50% for extra-adrenal abdominal pheochromocytoma and 10% and 5% for adrenal and familial forms respectively^[6,7]. However, in practice the diagnosis of malignant pheochromocytoma can only be determined by presence of recurrence or metastatic disease at a site where chromaffin cells do not normally exist. NF is the term given to two neurocutaneous genetic conditions. *NF1*, also known as von Recklinghausen's disease is the most common type of NF, with an incidence of approximately 1 in 2600 to 1 in 3000 individuals^[8]. Approximately half of the cases are familial while the remainder are new mutations^[9]. The hallmarks of *NF1* are the multiple café-au-lait spots and associated cutaneous neurofibromas. Pheochromocytoma has been clinically identified in 0.1%-5.7% of patients with NF. The *NF1* gene has been mapped to chromosome 17q11.2 and cloned^[10-12]. Since malignant pheochromocytoma is very rare in NF, we present a case with NF and metastatic pheochromocytoma in which genetic screening in *VHL*, Ret protooncogene and *SDH* were carried out to investigate the responsible genomic mutation.

MATERIALS AND METHODS

Biochemical testing and Localization Studies

Routine biochemical tests, evaluation of 24 h urine catecholamine metabolites, abdominal computed tomography or magnetic resonance imaging and ¹³¹Iodine-metaiodobenzylguanidine (¹³¹I-MIBG) therapy were carried out. The malignant pheochromocytoma was diagnosed according to the presence or absence of metastasis in radiological or pathological reports.

Genetic analysis

RET proto-oncogene mutation screening: Genomic DNA was extracted from peripheral lymphocytes using the salting out technique. RET proto-oncogene mutation screening for exons 10, 11, 13, 14, 15, 16 was performed polymerase chain reaction (PCR) and direct DNA sequencing using the assay described by Alvandi *et al.*^[13].

VHL gene mutation screening: For *VHL* gene mutation screening, analysis of *VHL* gene was performed using the protocol of Cruz *et al.*^[2,14]. Exons 1, 2, 3 of *VHL* gene were amplified by PCR with the following primers: 1F - 5' CCATCCTCTACCGAGCGCGCG 3'; 1R - 5' GGGCTTCAGACCGTGCTATCG 2; 3F - 5' TGCCAGCCACCGGTGTG 2; 3R - 5' GTCTATCCTGTACTTACCACAACA; 3F - 5' CACACTGCCACATACATGCACTC 3'; 3R - 5' ACTCATCAGTACCATCAAAAGCTG 3'. Both forward and reverse strands were subjected to direct sequencing after PCR amplification^[2].

SDH complex subunits B gene mutation screening:

The entire coding sequence of the succinate dehydrogenase complex subunits B (*SDHB*) gene was screened for the presence of pathogenic mutations by PCR-sequencing based on the assay described previously^[15].

RESULTS

Patient

A 45-year-old man presented with abdominal pain and hypertension over the previous year. The patient was a known case of *NF1* who presented at the age of 15 years with hyperpigmented and hypopigmented lesions on the trunk, arms, feet and axillary areas. Family history was positive for NF in his mother and brother. Biochemical tests including urine metanephrines and imaging were compatible with malignant pheochromocytoma. In scans there was a large mass in the left adrenal with a size of 120 mm × 70 mm and invasion to left kidney was reported. The patient underwent left adrenalectomy, nephrectomy and splenectomy. After surgery the symptoms improved and blood pressure was controlled. The patient had poor compliance in follow up. After 5 years he was admitted again for evaluation of a hypertensive crisis. Biochemical tests were again consistent with pheochromocytoma and disease relapse. Imaging study and liver biopsy confirmed metastatic pheochromocytoma in the

liver and para-aortic area. 131I-MIBG therapy was carried out.

Genetic analysis

RET proto-oncogene mutation screening: There was no pathogenic mutation in the RET proto-oncogene. Only three single nucleotide polymorphisms were identified in this patient as follows: (1) C1866T in exon 10, causes no AA change (P622P); (2) G2071A in exon 11, causes G691S; and (3) C2712G in exon 15, causes no AA change (S904S).

VHL gene and SDHB gene mutation screening: There was no VHL gene mutation. In addition, genetic sequencing of 8 exons of SDHB gene revealed no pathogenic mutation in this patient.

DISCUSSION

The family described in this study comprises individuals with NF and one member (a 45-year-old man) with hypertension diagnosed as malignant pheochromocytoma. Hypertension is a frequent finding in adults with NF1 and may develop during childhood although pheochromocytoma is a much less common etiology. In these patients, the catecholamine-secreting tumor is usually a solitary benign adrenal pheochromocytoma, occasionally bilateral adrenal pheochromocytoma, and rarely a peri-adrenal abdominal PGL. Although NF1 as an autosomal dominant disorder is the most common familial cancer syndrome predisposing to pheochromocytoma, the risk of pheochromocytoma in this disorder is only about 1%^[16,17].

Pheochromocytomas in patients with NF1 occur in the fifth decade. Our patient was a 45-year-old man with an unusual presentation of pheochromocytoma. Currently, except for the presence of the SDHB mutation, a large or an extra-adrenal primary tumor, there are no reliable markers for predicting a high likelihood of developing metastatic disease. Pheochromocytoma in NF is usually benign and unilateral. Based on genetic background our expectation before surgery was a benign non-metastatic tumor. As mentioned before, the patient had a metastatic tumor and after 5 years metastasis to liver and para-aortic lymph nodes led to deterioration in the clinical course of disease. It seems to us that a large mass (as detected in this patient initially) as well as local invasion are critical factors for predicting malignancy and may have the highest impact for detecting metastasis in future.

At first we treated the patient with surgical resection of the adrenal mass, but in follow up treatment of distance metastasis the only available modality was MIBG therapy. Given the positive MIBG scan, we predicted that the tumor would up take iodine. To date, beside surgery, 131I-MIBG therapy is the single most valuable option for malignant pheochromocytomas. Results of a phase II trial using high dose 131I-MIBG demonstrated 22% partial or complete response and 35% of patients having some degree of response (*i.e.*, biochemical) without dem-

onstrated progressive disease^[18]. After 6 mo follow up our patient is alive but needs antihypertensive drugs. In future, our plan could be chemoembolization of the liver if there is persistent disease. Mutation screening were negative in our patient except for three nucleotide changes in the RET gene. Among them, nucleotide change C1866T is a new SNP, while changes G2071A and C2712G have been reported in the literature as SNPs. None of these changes are causative mutations for medullary thyroid cancer (MTC) patients although they are more common in patients with MTC than in normal population. Whether there is an interaction between these polymorphisms and other genes related to NF is still a matter of debate.

Mutations in the NF1 gene result in loss of functional protein, causing the wide spectrum of clinical findings with NF1-associated tumors. No obvious genotype-phenotype correlation between small mutations (< 20 base pairs) of the NF1 gene and a specific phenotype have been demonstrated, with the exception of the c.2970-2972 delAAT (p.M990del) mutation that is associated with a very mild phenotype in the majority of cases^[19]. Genetic testing for NF1 is available but is not routinely performed, as the diagnosis is made based upon clinical phenotype.

In addition, epigenetic factors, particularly DNA methylation, may also play essential roles in regulation of RET, VHL and NF1 pathways. A recent study has identified methylated RET in colorectal cancer^[20]. It has been observed that the aberrant methylation of RET correlates with decreased RET expression, whereas the restoration of RET in colorectal cancer cell lines results in apoptosis^[21]. Other studies have found epigenetic regulation of VHL or NF1 genes in various carcinomas^[22,23]. Therefore, epigenetic regulation of involved genes may also contribute to the pathogenesis of disease in this patient and this requires further investigations.

ACKNOWLEDGMENTS

We gratefully thank this family for consenting to the publication of this study.

COMMENTS

Background

Neurofibromatosis (NF), is the term given to two neurocutaneous genetic conditions. NF type 1 (NF1), also known as von Recklinghausen's is the most common type of NF.

Research frontiers

Hypertension is a frequent finding in adults with NF1 and may develop during childhood but pheochromocytoma is a much less common etiology. In these patients, the catecholamine-secreting tumor is usually a solitary benign adrenal pheochromocytoma, occasionally bilateral adrenal pheochromocytoma, and rarely a peri adrenal abdominal paraganglioma.

Innovations and breakthroughs

At first we treated the patient with surgical resection of the adrenal mass, but in follow up for treatment of distance metastasis the only available modality was metaiodobenzylguanidine therapy.

Applications

Genetic testing for NF1 is available but is not routinely performed, as the diagnosis is made based upon clinical phenotype.

Peer review

This is a relatively interesting manuscript of a rare case report on Pheochromocytoma in *NF1*. Although mutational studies of potential related genes were performed, the negative findings do not provide any additional molecular data of interest.

REFERENCES

- 1 **Lenders JW**, Eisenhofer G, Mannelli M, Pacak K. Pheochromocytoma. *Lancet* 2005; **366**: 665-675 [PMID: 16112304]
- 2 **Hasani-Ranjbar S**, Amoli MM, Ebrahim-Habibi A, Haghpanah V, Hejazi M, Soltani A, Larijani B. Mutation screening of VHL gene in a family with malignant bilateral pheochromocytoma: from isolated familial pheochromocytoma to von Hippel-Lindau disease. *Fam Cancer* 2009; **8**: 465-471 [PMID: 19649731 DOI: 10.1007/s10689-009-9266-4]
- 3 **Hasani-Ranjbar S**, Amoli MM, Ebrahim-Habibi A, Gozashti MH, Khalili N, Sayyahpour FA, Hafeziyeh J, Soltani A, Larijani B. A new frameshift MEN1 gene mutation associated with familial malignant insulinomas. *Fam Cancer* 2011; **10**: 343-348 [PMID: 21184284 DOI: 10.1007/s10689-010-9412-z]
- 4 **Walther MM**, Herring J, Enquist E, Keiser HR, Linehan WM. von Recklinghausen's disease and pheochromocytomas. *J Urol* 1999; **162**: 1582-1586 [PMID: 10524872 DOI: 10.1016/S0022-5347(05)68171-2]
- 5 **Dluhy RG**. Pheochromocytoma--death of an axiom. *N Engl J Med* 2002; **346**: 1486-1488 [PMID: 12000821]
- 6 **Whalen RK**, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. *J Urol* 1992; **147**: 1-10 [PMID: 1729490]
- 7 **O'Riordain DS**, Young WF, Grant CS, Carney JA, van Heerden JA. Clinical spectrum and outcome of functional extraadrenal paraganglioma. *World J Surg* 1996; **20**: 916-921; discussion 922 [PMID: 8678971 DOI: 10.1007/s002689900139]
- 8 **Lammert M**, Friedman JM, Kluwe L, Mautner VF. Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. *Arch Dermatol* 2005; **141**: 71-74 [PMID: 15655144 DOI: 10.1001/archderm.141.1.71]
- 9 **North K**. Neurofibromatosis type 1: review of the first 200 patients in an Australian clinic. *J Child Neurol* 1993; **8**: 395-402 [PMID: 8228039 DOI: 10.1177/088307389300800421]
- 10 **Ledbetter DH**, Rich DC, O'Connell P, Leppert M, Carey JC. Precise localization of NF1 to 17q11.2 by balanced translocation. *Am J Hum Genet* 1989; **44**: 20-24 [PMID: 2491776]
- 11 **Shen MH**, Harper PS, Upadhyaya M. Molecular genetics of neurofibromatosis type 1 (NF1). *J Med Genet* 1996; **33**: 2-17 [PMID: 8825042 DOI: 10.1136/jmg.33.1.2]
- 12 **Feldkamp MM**, Gutmann DH, Guha A. Neurofibromatosis type 1: piecing the puzzle together. *Can J Neurol Sci* 1998; **25**: 181-191 [PMID: 9706718]
- 13 **Alvandi E**, Pedram M, Soroush AR, Naier BN, Akrami SM. Detection of RET Proto-oncogene Cys634Arg Mutation, the Cause of Medullary Thyroid Carcinoma, in an Iranian Child. *Iran J Pediatr* 2007; **17**: 301-305
- 14 **Cruz JB**, Fernandes LP, Clara SA, Conde SJ, Perone D, Kopp P, Nogueira CR. Molecular analysis of the Von Hippel-Lindau (VHL) gene in a family with non-syndromic pheochromocytoma: the importance of genetic testing. *Arq Bras Endocrinol Metabol* 2007; **51**: 1463-1467 [PMID: 18209888]
- 15 **Oishi Y**, Nagai S, Yoshida M, Fujisawa S, Sazawa A, Shinohara N, Nonomura K, Matsuno K, Shimizu C. Mutation analysis of the SDHB and SDHD genes in pheochromocytoma and paragangliomas: identification of a novel nonsense mutation (Q168X) in the SDHB gene. *Endocr J* 2010; **57**: 745-750 [PMID: 20505258]
- 16 **Huson SM**, Compston DA, Clark P, Harper PS. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. *J Med Genet* 1989; **26**: 704-711 [PMID: 2511318]
- 17 **Riccardi VM**. Neurofibromatosis: past, present, and future. *N Engl J Med* 1991; **324**: 1283-1285 [PMID: 1901626]
- 18 **Gonias S**, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, Damon L, Linker C, Sznawa A, Shiboski S, Fitzgerald P. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. *J Clin Oncol* 2009; **27**: 4162-4168 [PMID: 19636009]
- 19 **Upadhyaya M**, Huson SM, Davies M, Thomas N, Chuzhanova N, Giovannini S, Evans DG, Howard E, Kerr B, Griffiths S, Consoli C, Side L, Adams D, Pierpont M, Hachen R, Barnicoat A, Li H, Wallace P, Van Biervliet JP, Stevenson D, Viskochil D, Baralle D, Haan E, Riccardi V, Turnpenny P, Lazaro C, Messiaen L. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. *Am J Hum Genet* 2007; **80**: 140-151 [PMID: 17160901]
- 20 **Luo Y**, Tsuchiya KD, Il Park D, Fausel R, Kannigurn S, Welsh P, Dzieciatkowski S, Wang J, Grady WM. RET is a potential tumor suppressor gene in colorectal cancer. *Oncogene* 2013; **32**: 2037-2047 [PMID: 22751117 DOI: 10.1038/onc.2012.225]
- 21 **Vanharanta S**, Shu W, Brenet F, Hakimi AA, Heguy A, Viale A, Reuter VE, Hsieh JJ, Scandura JM, Massagué J. Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. *Nat Med* 2013; **19**: 50-56 [PMID: 23223005]
- 22 **Moore LE**, Nickerson ML, Brennan P, Toro JR, Jaeger E, Rinsky J, Han SS, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Schmidt LS, Lenz P, Karami S, Linehan WM, Merino M, Chanock S, Boffetta P, Chow WH, Waldman FM, Rothman N. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors. *PLoS Genet* 2011; **7**: e1002312 [PMID: 22022277 DOI: 10.1371/journal.pgen.1002312]
- 23 **Gutmann DH**, McLellan MD, Hussain I, Wallis JW, Fulton LL, Fulton RS, Magrini V, Demeter R, Wylie T, Kandoth C, Leonard JR, Guha A, Miller CA, Ding L, Mardis ER. Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma. *Genome Res* 2013; **23**: 431-439 [PMID: 23222849]

P- Reviewers Guo ZS, Rey JA, Timmers HJLM
S- Editor Zhai HH **L- Editor** Hughes D **E- Editor** Zheng XM



GENERAL INFORMATION

World Journal of Medical Genetics (*World J Med Genet*, *WJMG*, online ISSN 2220-3184, DOI: 10.5496) is a peer-reviewed open access (OA) academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

Aim and scope

WJMG covers topics concerning genes and the pathology of human disease, molecular analysis of simple and complex genetic traits, cancer genetics, epigenetics, gene therapy, developmental genetics, regulation of gene expression, strategies and technologies for extracting function from genomic data, pharmacological genomics, genome evolution. The current columns of *WJMG* include editorial, frontier, diagnostic advances, therapeutics advances, field of vision, mini-reviews, review, topic highlight, medical ethics, original articles, case report, clinical case conference (Clinicopathological conference), and autobiography.

We encourage authors to submit their manuscripts to *WJMG*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

WJMG is edited and published by Baishideng Publishing Group (BPG). BPG has a strong professional editorial team composed of science editors, language editors and electronic editors. BPG currently publishes 43 OA clinical medical journals, including 42 in English, has a total of 15471 editorial board members or peer reviewers, and is a world first-class publisher.

Columns

The columns in the issues of *WJMG* will include: (1) Editorial: The editorial board members are invited to make comments on an important topic in their field in terms of its current research status and future directions to lead the development of this discipline; (2) Frontier: The editorial board members are invited to select a highly cited cutting-edge original paper of his/her own to summarize major findings, the problems that have been resolved and remain to be resolved, and future research directions to help readers understand his/her important academic point of view and future research directions in the field; (3) Diagnostic Advances: The editorial board members are invited to write high-quality diagnostic advances in their field to improve the diagnostic skills of readers. The topic covers general clinical diagnosis, differential diagnosis, pathological diagnosis, laboratory diagnosis, imaging diagnosis, endoscopic diagnosis, biotechnological diagnosis, functional diagnosis, and physical diagnosis; (4) Therapeutics Advances: The editorial board members are invited to write high-quality therapeutic advances in their field to help improve the therapeutic skills of readers. The topic covers medication therapy, psychotherapy, physical therapy, replacement therapy, interventional therapy, minimally invasive therapy, endoscopic therapy, transplantation therapy, and surgical therapy; (5) Field of Vision: The editorial board members are invited to write commentaries on classic articles, hot topic articles, or latest articles to keep readers at the forefront of research and increase their levels of clinical research. Classic articles refer to papers that are included in Web of Knowledge and have received a large number of citations (ranking in the top 1%) after being published for more than years, reflecting the quality and impact of papers. Hot topic articles refer to papers that are included in Web of Knowledge and have received a large number of citations after being published for no more than

2 years, reflecting cutting-edge trends in scientific research. Latest articles refer to the latest published high-quality papers that are included in PubMed, reflecting the latest research trends. These commentary articles should focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions. Basic information about the article to be commented (including authors, article title, journal name, year, volume, and inclusive page numbers); (6) Minireviews: The editorial board members are invited to write short reviews on recent advances and trends in research of molecular biology, genomics, and related cutting-edge technologies to provide readers with the latest knowledge and help improve their diagnostic and therapeutic skills; (7) Review: To make a systematic review to focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions; (8) Topic Highlight: The editorial board members are invited to write a series of articles (7-10 articles) to comment and discuss a hot topic to help improve the diagnostic and therapeutic skills of readers; (9) Medical Ethics: The editorial board members are invited to write articles about medical ethics to increase readers' knowledge of medical ethics. The topic covers international ethics guidelines, animal studies, clinical trials, organ transplantation, etc.; (10) Clinical Case Conference or Clinicopathological Conference: The editorial board members are invited to contribute high-quality clinical case conference; (11) Original Articles: To report innovative and original findings in medical genetics; (12) Brief Articles: To briefly report the novel and innovative findings in medical genetics; (13) Meta-Analysis: Covers the systematic review, mixed treatment comparison, meta-regression, and overview of reviews, in order to summarize a given quantitative effect, e.g., the clinical effectiveness and safety of clinical treatments by combining data from two or more randomized controlled trials, thereby providing more precise and externally valid estimates than those which would stem from each individual dataset if analyzed separately from the others; (15) Letters to the Editor: To discuss and make reply to the contributions published in *WJMG*, or to introduce and comment on a controversial issue of general interest; (16) Book Reviews: To introduce and comment on quality monographs of medical genetics; and (17) Autobiography: The editorial board members are invited to write their autobiography to provide readers with stories of success or failure in their scientific research career. The topic covers their basic personal information and information about when they started doing research work, where and how they did research work, what they have achieved, and their lessons from success or failure.

Name of journal

World Journal of Medical Genetics

ISSN

ISSN 2220-3184 (online)

Launch date

December 27, 2011

Frequency

Quarterly

Editor-in-Chief

Hans van Bokhoven, Professor, PhD, Department of Human

Instructions to authors

Genetics and Cognitive Neurosciences, Radboud university Nijmegen
Medical centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands

Editorial office

Jin-Lei Wang, Director
Xiu-Xia Song, Vice Director
World Journal of Medical Genetics
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-85381891
Fax: +86-10-85381893
E-mail: wjmg@wjgnet.com
<http://www.wjgnet.com>

Publisher

Baishideng Publishing Group Co., Limited
Flat C, 23/F, Lucky Plaza, 315-321 Lockhart Road,
Wan Chai, Hong Kong, China
Telephone: +852-58042046
Fax: +852-31158812
E-mail: bpgoffice@wjgnet.com
<http://www.wjgnet.com>

Production center

Beijing Baishideng BioMed Scientific Co., Limited
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-85381892
Fax: +86-10-85381893

Representative office

USA Office
8226 Regency Drive,
Pleasanton, CA 94588-3144, United States

Instructions to authors

Full instructions are available online at http://www.wjgnet.com/2220-3184/g_info_20100722180909.htm.

Indexed and Abstracted in

Digital Object Identifier.

SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Ridit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word "significantly" should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJMG* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests

in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: http://www.icmje.org/ethical_4conflicts.html.

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified.

A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/esps/>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS (http://www.wjgnet.com/2220-3184/g_info_20100722180909.htm) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to wjmg@wjgnet.com, or by telephone: +86-10-85381892. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

Title page

Title: Title should be less than 12 words.

Running title: A short running title of less than 6 words should be provided.

Authorship: Authorship credit should be in accordance with the standard proposed by ICMJE, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

Institution: Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

Author contributions: The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

Supportive foundations: The complete name and number of supportive foundations should be provided, *e.g.*, Supported by National Natural Science Foundation of China, No. 30224801

Correspondence to: Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, Uni-

versity of California, Box 0538, San Francisco, CA 94143, United States. montgomery.bissell@ucsf.edu

Telephone and fax: Telephone and fax should consist of +, country number, district number and telephone or fax number, *e.g.*, Telephone: +86-10-85381892 Fax: +86-10-85381893

Peer reviewers: All articles received are subject to peer review. Normally, three experts are invited for each article. Decision on acceptance is made only when at least two experts recommend publication of an article. All peer-reviewers are acknowledged on Express Submission and Peer-review System website.

Abstract

There are unstructured abstracts (no less than 200 words) and structured abstracts. The specific requirements for structured abstracts are as follows:

An informative, structured abstract should accompany each manuscript. Abstracts of original contributions should be structured into the following sections: AIM (no more than 20 words; Only the purpose of the study should be included. Please write the Aim in the form of "To investigate/study/..."), METHODS (no less than 140 words for Original Articles; and no less than 80 words for Brief Articles), RESULTS (no less than 150 words for Original Articles and no less than 120 words for Brief Articles; You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, *e.g.*, 6.92 ± 3.86 vs 3.61 ± 1.67 , $P < 0.001$), and CONCLUSION (no more than 26 words).

Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

Core tip

Please write a summary of less than 100 words to outline the most innovative and important arguments and core contents in your paper to attract readers.

Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS AND DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both.

Illustrations

Figures should be numbered as 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ... *etc.* It is our principle to publish high resolution-figures for the E-versions.

Tables

Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

Notes in tables and illustrations

Data that are not statistically significant should not be noted. ^a*P* <

Instructions to authors

0.05, ^b $P < 0.01$ should be noted ($P > 0.05$ should not be noted). If there are other series of P values, ^c $P < 0.05$ and ^d $P < 0.01$ are used. A third series of P values can be expressed as ^e $P < 0.05$ and ^f $P < 0.01$. Other notes in tables or under illustrations should be expressed as ¹F, ²F, ³F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, etc., in a certain sequence.

Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

REFERENCES

Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability^[1,2]". If references are cited directly in the text, they should be put together within the text, for example, "From references^[19,22-24], we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g., PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

Format

Journals

English journal article (list all authors and include the PMID where applicable)

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarhoea. *Shijie Huaren Xiaohua Zazhi* 1999; **7**: 285-287

In press

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature

of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

Organization as author

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMID:2516377 DOI:10.1161/01.HYP.0000035706.28494.09]

Both personal authors and an organization as author

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

No author given

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

Volume with supplement

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

Issue with no volume

- 8 **Banitt DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; (**401**): 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

No volume or issue

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS-A Careaction* 2002; 1-6 [PMID: 12154804]

Books

Personal author(s)

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

Chapter in a book (list all authors)

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

Author(s) and editor(s)

- 12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wiczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

Conference proceedings

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

Conference paper

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. *Emerg Infect Dis* serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

Patent (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

Statistical data

Write as mean \pm SD or mean \pm SE.

Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as χ^2 (in Greek), related coefficient as *r* (in italics), degree of freedom as ν (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h; blood glucose concentration, *c* (glucose) 6.4 ± 2.1 mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 24.5 $\mu\text{g/L}$; CO₂ volume fraction, 50 mL/L CO₂, not 5% CO₂; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, etc. Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantum numbers can be found at: http://www.wjgnet.com/2220-3184/g_info_20100725073806.htm.

Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, etc.

Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kho I*, *Kpn I*, etc.

Biology: *H. pylori*, *E. coli*, etc.

Examples for paper writing

All types of articles' writing style and requirement will be found in the link: <http://www.wjgnet.com/esps/NavigationInfo.aspx?id=15>

RESUBMISSION OF THE REVISED MANUSCRIPTS

Authors must revise their manuscript carefully according to the revision policies of Baishideng Publishing Group Co., Limited. The revised version, along with the signed copyright transfer agreement,

responses to the reviewers, and English language Grade A certificate (for non-native speakers of English), should be submitted to the online system *via* the link contained in the e-mail sent by the editor. If you have any questions about the revision, please send e-mail to esps@wjgnet.com.

Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A.

Copyright assignment form

Please download a Copyright assignment form from http://www.wjgnet.com/2220-3184/g_info_20100725073726.htm.

Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: http://www.wjgnet.com/2220-3184/g_info_20100725073445.htm.

Proof of financial support

For papers supported by a foundation, authors should provide a copy of the approval document and serial number of the foundation.

Statement about anonymous publication of the peer reviewers' comments

In order to increase the quality of peer review, push authors to carefully revise their manuscripts based on the peer reviewers' comments, and promote academic interactions among peer reviewers, authors and readers, we decide to anonymously publish the reviewers' comments and author's responses at the same time the manuscript is published online.

PUBLICATION FEE

WJMG is an international, peer-reviewed, OA online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium and format, provided the original work is properly cited. The use is non-commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. Publication fee: 600 USD per article. All invited articles are published free of charge.



百世登

Baishideng®

Published by **Baishideng Publishing Group Co., Limited**

Flat C, 23/F., Lucky Plaza,

315-321 Lockhart Road, Wan Chai, Hong Kong, China

Fax: +852-65557188

Telephone: +852-31779906

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

